Hun Ju Lee

6.0k total citations
114 papers, 2.0k citations indexed

About

Hun Ju Lee is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Hun Ju Lee has authored 114 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Pathology and Forensic Medicine, 61 papers in Oncology and 34 papers in Genetics. Recurrent topics in Hun Ju Lee's work include Lymphoma Diagnosis and Treatment (77 papers), CAR-T cell therapy research (34 papers) and Chronic Lymphocytic Leukemia Research (32 papers). Hun Ju Lee is often cited by papers focused on Lymphoma Diagnosis and Treatment (77 papers), CAR-T cell therapy research (34 papers) and Chronic Lymphocytic Leukemia Research (32 papers). Hun Ju Lee collaborates with scholars based in United States, Italy and Canada. Hun Ju Lee's co-authors include Abhishek Srivastava, Jason R. Westin, Sattva S. Neelapu, Loretta J. Nastoupil, Luis Fayad, Michael Wang, Margaret A. Shipp, Meir Wetzler, Eunice S. Wang and Philippe Armand and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Hun Ju Lee

105 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hun Ju Lee United States 22 1.2k 942 324 309 300 114 2.0k
Michael Dickinson Australia 26 1.4k 1.2× 1.1k 1.2× 394 1.2× 343 1.1× 273 0.9× 188 2.8k
Annette E. Hay Canada 15 1.0k 0.9× 846 0.9× 232 0.7× 219 0.7× 154 0.5× 82 1.6k
Lorenz Truemper Germany 18 703 0.6× 820 0.9× 372 1.1× 177 0.6× 292 1.0× 79 1.4k
Chadi Nabhan United States 25 699 0.6× 1.2k 1.2× 821 2.5× 422 1.4× 244 0.8× 139 1.9k
Lynn Navale United States 17 1.7k 1.4× 863 0.9× 212 0.7× 317 1.0× 137 0.5× 59 2.1k
Lauren Harrison United States 24 512 0.4× 530 0.6× 206 0.6× 219 0.7× 190 0.6× 83 1.5k
Ulrich Kaiser Germany 25 1.4k 1.3× 1.9k 2.1× 1.1k 3.4× 239 0.8× 571 1.9× 118 2.8k
Pratik S. Multani United States 19 1.2k 1.0× 1.4k 1.5× 424 1.3× 351 1.1× 173 0.6× 64 2.8k
Chan Y. Cheah Australia 30 1.7k 1.5× 2.3k 2.4× 1.2k 3.8× 441 1.4× 614 2.0× 196 3.5k
Morten Mau‐Sørensen Denmark 28 1.2k 1.0× 310 0.3× 570 1.8× 276 0.9× 212 0.7× 130 2.7k

Countries citing papers authored by Hun Ju Lee

Since Specialization
Citations

This map shows the geographic impact of Hun Ju Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hun Ju Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hun Ju Lee more than expected).

Fields of papers citing papers by Hun Ju Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hun Ju Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hun Ju Lee. The network helps show where Hun Ju Lee may publish in the future.

Co-authorship network of co-authors of Hun Ju Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Hun Ju Lee. A scholar is included among the top collaborators of Hun Ju Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hun Ju Lee. Hun Ju Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pradeep, Roshini, Ranjit Nair, Luis Malpica, et al.. (2024). Brentuximab Associated Guillain-Barré Syndrome (BV-GBS): Case Series and a Review of Pharmacovigilance FDA Adverse Reporting System (FAERS). Blood. 144(Supplement 1). 7776–7776.
3.
Pinnix, Chelsea C., Bouthaina S. Dabaja, Jillian R. Gunther, et al.. (2024). Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma. JAMA Oncology. 10(9). 1195–1195. 7 indexed citations
4.
5.
Iyer, Swaminathan P., Lei Feng, Jie Xu, et al.. (2023). TCL-275 Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients With Relapsed or Refractory T-Cell Lymphoma (TCL) With Survival Analysis. Clinical Lymphoma Myeloma & Leukemia. 23. S468–S469. 3 indexed citations
6.
Armand, Philippe, Pier Luigi Zinzani, Hun Ju Lee, et al.. (2023). Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 142(10). 878–886. 39 indexed citations
7.
Stuver, Robert, Steven M. Horwitz, Ranjana H. Advani, et al.. (2023). Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma. British Journal of Haematology. 202(3). 525–529. 7 indexed citations
8.
Marques‐Piubelli, Mario L., Edwin Roger Parra, Lei Feng, et al.. (2022). SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Advances. 6(11). 3286–3293. 7 indexed citations
9.
Jain, Preetesh, Rashmi Kanagal‐Shamanna, Shaojun Zhang, et al.. (2021). Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology. 96(5). E137–E140. 5 indexed citations
10.
Hadidi, Samer Al, Hubert H. Chuang, Roberto N. Miranda, & Hun Ju Lee. (2020). Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(2). e105–e111. 4 indexed citations
11.
Lee, Hun Ju, Michael Y. Choi, Tanya Siddiqi, et al.. (2020). Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. Blood. 136(Supplement 1). 45–46. 5 indexed citations
12.
Lee, Hun Ju, et al.. (2019). Emerging treatment options for patients with p53-pathway-deficient CLL. Therapeutic Advances in Hematology. 10. 153183132–153183132. 13 indexed citations
13.
Pinnix, Chelsea C., Jillian R. Gunther, Sarah A. Milgrom, et al.. (2019). Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. International Journal of Radiation Oncology*Biology*Physics. 104(2). 447–455. 36 indexed citations
14.
Jain, Preetesh, Rashmi Kanagal‐Shamanna, Shaojun Zhang, et al.. (2018). Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood. 132(Supplement 1). 4151–4151. 5 indexed citations
15.
Jain, Preetesh, Jorge Romaguera, Hun Ju Lee, et al.. (2018). Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). British Journal of Haematology. 182(3). 404–411. 46 indexed citations
16.
Strati, Paolo, Yasuhiro Oki, Luis Fayad, et al.. (2014). A Phase 1 Trial of Alisertib and Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas. Blood. 130(21). 4074–4074. 19 indexed citations
17.
Nguyen, David, et al.. (2010). Delayed Hemolytic Transfusion Reaction due to Anti-Jkb: Case Report Highlighting the Importance of Early Blood Bank Consultation and Literature Review. North American Journal of Medicine and Science. 3(4). 187–187. 3 indexed citations
18.
Grimm, Curtis M., Hun Ju Lee, & Ken G. Smith. (2005). Strategy As Action: Competitive Dynamics and Competitive Advantage. OUP Catalogue. 74 indexed citations
19.
Srivastava, Abhishek & Hun Ju Lee. (2005). Predicting Order and Timing of New Product Moves: The Role of Top Management in Corporate Entrepreneurship. SSRN Electronic Journal. 2 indexed citations
20.
Srivastava, Abhishek & Hun Ju Lee. (2004). Predicting order and timing of new product moves: the role of top management in corporate entrepreneurship. Journal of Business Venturing. 20(4). 459–481. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Dickinson Breakdown of academic impact, for papers by Annette E. Hay Breakdown of academic impact, for papers by Lorenz Truemper Breakdown of academic impact, for papers by Chadi Nabhan Breakdown of academic impact, for papers by Lynn Navale Breakdown of academic impact, for papers by Lauren Harrison Breakdown of academic impact, for papers by Ulrich Kaiser Breakdown of academic impact, for papers by Pratik S. Multani Breakdown of academic impact, for papers by Chan Y. Cheah Breakdown of academic impact, for papers by Morten Mau‐Sørensen
Rankless by CCL
2026